Home » Stocks » PSTX

Poseida Therapeutics, Inc. (PSTX)

Stock Price: $11.07 USD -0.15 (-1.34%)
Updated November 24, 2:52 PM EST - Market open

Stock Price Chart

Key Info

Market Cap 684.35M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 61.82M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 24
Last Price $11.07
Previous Close $11.22
Change ($) -0.15
Change (%) -1.34%
Day's Open 11.22
Day's Range 10.82 - 11.41
Day's Volume 36,317
52-Week Range 7.63 - 17.62

More Stats

Market Cap 684.35M
Enterprise Value 401.76M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 61.82M
Float 23.86M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.00M
Short Ratio 8.76
Short % of Float 4.21%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 11.97
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 282.58M
Net Cash / Share 4.57
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(125.84% upside)
Current: $11.07
Target: 25.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-85.53-41.99
Net Income-86.53-44.40
Shares Outstanding12.6212.18
Earnings Per Share-6.86-3.64
Operating Cash Flow-64.39-38.01
Capital Expenditures-5.16-1.28
Free Cash Flow-69.55-39.30
Cash & Equivalents12530.40
Total Debt29.1419.09
Net Cash / Debt96.1811.31
Book Value-150-76.72
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Poseida Therapeutics, Inc.
Country United States
Employees 186
CEO Eric M. Ostertag

Stock Information

Ticker Symbol PSTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PSTX
IPO Date July 10, 2020


Poseida Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed gene therapies for rare diseases. In addition, it offers CAR-T therapies for the treatment for cancer. Further, it offers gene therapies for rare and life-threatening diseases, including Ornithine transcarbamylase (OTC) deficiency and methylmalonic acidemia (MMA), and genetic liver diseases. The company was founded in 2014 and is headquartered in San Diego, California.